Factors involved in the delay of treatment initiation for cervical cancer patients

Abstract Cervical cancer ranks as the fourth leading cause of cancer death in women worldwide. In Taiwan, although the universal health insurance system has achieved 99.9% coverage and ensured easy access to medical care, some cervical cancer patients continue to delay initiation of definitive treatment after diagnosis. This study focused on cervical cancer patients who delayed treatment for at least 4 months, and examined the characteristics, related factors, and survival in these patients. Data on patients with a new confirmed diagnosis of cervical cancer by the International Federation of Gynecology and Obstetrics (FIGO) staging system between 2005 and 2010 were obtained from the National Health Insurance Research Database and the Taiwan Cancer Registry. Logistic regression analysis was performed to analyze the association of various factors with treatment delay. The Cox proportional hazards model was used to analyze the effects of various factors on mortality risk. The rate of treatment delay for cervical cancer decreased steadily from 6.46% in 2005 to 2.48% in 2010. Higher rates of treatment delay were observed among patients who were aged ≥75 years (9.91%), had severe comorbidity, had stage IV (9.50%), diagnosing hospital level at nonmedical center, or at public hospital ownership. Factors that correlated with treatment delay were age ≥75 years (odds ratio [OR] = 2.42), higher comorbidity Charlson comorbidity index (CCI) 4–6, or ≥7 (OR = 1.60, 2.00), cancer stage IV (OR = 2.60), the diagnosing hospital being a regional, district hospital, or other (OR = 3.00, 4.01, 4.60), and at public hospital ownership. Those who delayed treatment had 2.31 times the mortality risk of those who underwent timely treatment (P < 0.05). Delayed cervical cancer treatment in Taiwan was associated with age, comorbidity, cancer stage, diagnosing hospital level, and hospital ownership. Delaying treatment for ≥4 months substantially raised mortality risk in cervical cancer patients.

[1]  J. Clarke,et al.  Medicine , 1907, Bristol medico-chirurgical journal.

[2]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[3]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[4]  S. Lauri,et al.  Cancer Patients’ Views and Experiences of Participation in Care and Decision Making , 2001, Nursing ethics.

[5]  M. Coleman,et al.  Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe , 2003, International journal of cancer.

[6]  S. Huchcroft,et al.  Cancer patients who refuse treatment , 1993, Cancer Causes & Control.

[7]  C. Haie-meder,et al.  Management and clinical outcomes of pregnant patients with invasive cervical cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. E,et al.  Radical radiotherapy for cervix cancer: the effect of waiting time on outcome. , 2005, International journal of radiation oncology, biology, physics.

[9]  Xianglin L. Du,et al.  Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts. , 2006, Gynecologic oncology.

[10]  B. Monk,et al.  Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. , 2008, American journal of obstetrics and gynecology.

[11]  J. Manson,et al.  Predicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention , 2011, Cancer Prevention Research.

[12]  Hongbing Shen,et al.  Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. , 2011, Lung cancer.

[13]  Prognostic factors in stage IA–IIA cervical cancer patients treated surgically: does the waiting time to the operation affect survival? , 2012, Archives of Gynecology and Obstetrics.

[14]  R. Konigsberg.  Refuseniks. Why some cancer patients reject their doctor's advice. , 2011, Time.

[15]  J. Grutsch,et al.  Beliefs and perceptions of women with newly diagnosed breast cancer who refused conventional treatment in favor of alternative therapies. , 2012, The oncologist.

[16]  Chun-Yi Liu,et al.  Characteristics, survival, and related factors of newly diagnosed colorectal cancer patients refusing cancer treatments under a universal health insurance program , 2014, BMC Cancer.

[17]  A. Ziogas,et al.  Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity. , 2013, JAMA surgery.

[18]  Gerard Rushton,et al.  Who does not receive treatment for cancer? , 2013, Journal of oncology practice.

[19]  Y. Hsu,et al.  Health examination utilization in the visually disabled population in Taiwan: a nationwide population-based study , 2013, BMC Health Services Research.

[20]  J. Jassem,et al.  Delays in diagnosis and treatment of breast cancer: a multinational analysis. , 2014, European journal of public health.

[21]  L. Hogen,et al.  Effect of Treatment Delay on Survival in Patients With Cervical Cancer: A Historical Cohort Study , 2014, International Journal of Gynecologic Cancer.

[22]  P. Kung,et al.  Factors Associated with Lung Cancer Patients Refusing Treatment and Their Survival: A National Cohort Study under a Universal Health Insurance in Taiwan , 2014, PloS one.

[23]  P. Kung,et al.  Characteristics of the Delayed or Refusal Therapy in Breast Cancer Patients: A Longitudinal Population-Based Study in Taiwan , 2015, PloS one.

[24]  D. Strategies.  Getting a Second Opinion , 2018 .